The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
ST Diepstraten, MA Anderson, PE Czabotar… - Nature Reviews …, 2022 - nature.com
Apoptosis is a form of programmed cell death that is regulated by the balance between
prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a …
prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a …
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell …
The incidence of renal cell carcinoma (RCC) is increasing worldwide with an approximate
20% mortality rate. The challenge in RCC is the therapy-resistance. Cancer resistance to …
20% mortality rate. The challenge in RCC is the therapy-resistance. Cancer resistance to …
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
B-cell lymphoma extra large (BCL-XL) is a well-validated cancer target. However, the on-
target and dose-limiting thrombocytopenia limits the use of BCL-XL inhibitors, such as …
target and dose-limiting thrombocytopenia limits the use of BCL-XL inhibitors, such as …
AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells
J Cidado, S Boiko, T Proia, D Ferguson… - Clinical cancer …, 2020 - AACR
Abstract Purpose: Cyclin-dependent kinase 9 (CDK9) is a transcriptional regulator and
potential therapeutic target for many cancers. Multiple nonselective CDK9 inhibitors have …
potential therapeutic target for many cancers. Multiple nonselective CDK9 inhibitors have …
[HTML][HTML] Recent advances in the development of Mcl-1 inhibitors for cancer therapy
AW Hird, AE Tron - Pharmacology & therapeutics, 2019 - Elsevier
Dysregulation of the mitochondrial apoptotic pathway controlled by members of the Bcl-2
protein family plays a central role in cancer development and resistance to conventional …
protein family plays a central role in cancer development and resistance to conventional …
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
Background Patients with advanced T cell lymphomas (TCLs) have limited therapeutic
options and poor outcomes in part because their TCLs evade apoptosis through …
options and poor outcomes in part because their TCLs evade apoptosis through …
[HTML][HTML] Recent advances in PROTACs for drug targeted protein research
Proteolysis-targeting chimera (PROTAC) is a heterobifunctional molecule. Typically,
PROTAC consists of two terminals which are the ligand of the protein of interest (POI) and …
PROTAC consists of two terminals which are the ligand of the protein of interest (POI) and …
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216
Pancreatic cancer is the third most common cause of cancer-related deaths in the United
States. Although gemcitabine is the standard of care for most patients with pancreatic …
States. Although gemcitabine is the standard of care for most patients with pancreatic …
Targeting MCL-1 protein to treat cancer: opportunities and challenges
SI Tantawy, N Timofeeva, A Sarkar, V Gandhi - Frontiers in oncology, 2023 - frontiersin.org
Evading apoptosis has been linked to tumor development and chemoresistance. One
mechanism for this evasion is the overexpression of prosurvival B-cell lymphoma-2 (BCL-2) …
mechanism for this evasion is the overexpression of prosurvival B-cell lymphoma-2 (BCL-2) …
Vibrio splendidus infection promotes circRNA-FGL1-regulated coelomocyte apoptosis via competitive binding to Myc with the deubiquitinase OTUB1 in Apostichopus …
M Guo, X Li, W Tao, F Teng, C Li - Plos Pathogens, 2024 - journals.plos.org
Circular RNAs (circRNAs) are involved in various physiological and pathological processes
in both vertebrates and invertebrates. However, most studies on circRNAs have focused on …
in both vertebrates and invertebrates. However, most studies on circRNAs have focused on …